VKTX vs. PRTA, ICPT, PBYI, MRNS, ALNY, GMAB, TEVA, RPRX, BGNE, and BMRN
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Prothena (PRTA), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI), Marinus Pharmaceuticals (MRNS), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), BeiGene (BGNE), and BioMarin Pharmaceutical (BMRN).
Viking Therapeutics (NASDAQ:VKTX) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.
Prothena received 1 more outperform votes than Viking Therapeutics when rated by MarketBeat users. However, 79.76% of users gave Viking Therapeutics an outperform vote while only 70.67% of users gave Prothena an outperform vote.
Viking Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
In the previous week, Prothena had 1 more articles in the media than Viking Therapeutics. MarketBeat recorded 11 mentions for Prothena and 10 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.84 beat Prothena's score of 0.75 indicating that Viking Therapeutics is being referred to more favorably in the media.
Viking Therapeutics presently has a consensus target price of $112.38, indicating a potential upside of 80.49%. Prothena has a consensus target price of $67.00, indicating a potential upside of 221.96%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than Viking Therapeutics.
Viking Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -193.17%. Viking Therapeutics' return on equity of -18.41% beat Prothena's return on equity.
76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 4.7% of Viking Therapeutics shares are owned by insiders. Comparatively, 28.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Viking Therapeutics has higher earnings, but lower revenue than Prothena. Viking Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Summary
Viking Therapeutics beats Prothena on 11 of the 18 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
